Technical Analysis for ALKS - Alkermes plc

Grade Last Price % Change Price Change
D 27.53 -4.24% -1.22
ALKS closed down 4.24 percent on Monday, March 18, 2024, on 1.17 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish -4.24%
Volume Surge Other -4.24%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 8 hours ago
1.5x Volume Pace about 12 hours ago
Lower Bollinger Band Support about 12 hours ago
Down 3% about 12 hours ago
Down 1 ATR about 12 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Alkermes plc Description

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Diabetes Alcohol Surgery Chemotherapy Hypertension Opioids Schizophrenia Lipid Multiple Sclerosis Cholesterol Depressive Disorder Morphinans Neurochemistry Organic Chemistry Constipation Hyperactivity Disorder Nausea Angina Obsessive Compulsive Disorder Treatment Of Schizophrenia Type I Diabetes Cachexia Type II Diabetes Atypical Antipsychotics Opioid Receptors Transplant Rejection Treatment Of Multiple Sclerosis Cocaine Luvox Cr Opioid Antagonists Opioid Induced Constipation Pharmaceutical Wholesalers Spasticity Zanaflex

Is ALKS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 33.71
52 Week Low 22.01
Average Volume 1,938,875
200-Day Moving Average 28.31
50-Day Moving Average 28.57
20-Day Moving Average 29.29
10-Day Moving Average 28.84
Average True Range 0.89
RSI (14) 40.12
ADX 14.48
+DI 20.77
-DI 25.51
Chandelier Exit (Long, 3 ATRs) 30.21
Chandelier Exit (Short, 3 ATRs) 30.15
Upper Bollinger Bands 30.65
Lower Bollinger Band 27.94
Percent B (%b) -0.15
BandWidth 9.27
MACD Line -0.06
MACD Signal Line 0.18
MACD Histogram -0.2464
Fundamentals Value
Market Cap 4.59 Billion
Num Shares 167 Million
EPS 1.24
Price-to-Earnings (P/E) Ratio 22.20
Price-to-Sales 2.87
Price-to-Book 3.36
PEG Ratio -1057.29
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.50
Resistance 3 (R3) 29.70 29.24 29.17
Resistance 2 (R2) 29.24 28.74 29.14 29.06
Resistance 1 (R1) 28.39 28.43 28.16 28.19 28.95
Pivot Point 27.93 27.93 27.82 27.83 27.93
Support 1 (S1) 27.08 27.43 26.85 26.88 26.11
Support 2 (S2) 26.62 27.12 26.52 26.00
Support 3 (S3) 25.77 26.62 25.89
Support 4 (S4) 25.57